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Abstract
Background: Prostate cancer is the most commonly diagnosed malignancy among men. The Discovery of new
agents for the treatment of prostate cancer is urgently needed. Compound WZ35, a novel analog of the natural
product curcumin, exhibited good anti-prostate cancer activity, with an IC50 of 2.2 μM in PC-3 cells. However, the
underlying mechanism of WZ35 against prostate cancer cells is still unclear.
Methods: Human prostate cancer PC-3 cells and DU145 cells were treated with WZ35 for further proliferation,
apoptosis, cell cycle, and mechanism analyses. NAC and CHOP siRNA were used to validate the role of ROS and ER
stress, respectively, in the anti-cancer actions of WZ35.
Results: Our results show that WZ35 exhibited much higher cell growth inhibition than curcumin by inducing ER
stress-dependent cell apoptosis in human prostate cells. The reduction of CHOP expression by siRNA partially
abrogated WZ35-induced cell apoptosis. WZ35 also dose-dependently induced cell cycle arrest in the G2/M phase.
Furthermore, we found that WZ35 treatment for 30 min significantly induced reactive oxygen species (ROS)
production in PC-3 cells. Co-treatment with the ROS scavenger NAC completely abrogated the induction of WZ35
on cell apoptosis, ER stress activation, and cell cycle arrest, indicating an upstream role of ROS generation in
mediating the anti-cancer effect of WZ35.
Conclusions: Taken together, this work presents the novel anticancer candidate WZ35 for the treatment of prostate
cancer, and importantly, reveals that increased ROS generation might be an effective strategy in human prostate
cancer treatment.
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Background
Prostate cancer is the most commonly diagnosed malig-
nancy among men in industrialized countries, account-
ing for the second leading cause of cancer-related death.
Conventional therapies produce a high rate of cure for
patients with localized prostate cancer by surgical ther-
apy, but there is no cure once the disease has spread
beyond the prostate. Traditionally, the treatment of
prostate cancer has been based on the deprivation of an-
drogens to the developing tumor. Though initially suc-
cessful, this form of therapy fails in advanced stages of
the disease, as the cells develop the ability to sustain
growth and proliferation even in the absence of andro-
gens, thus acquiring androgen resistance [1]. In addition,
these tumors tend to be highly resistant to conventional
cytotoxic agents such as cisplatin. Presently available
treatments for advanced hormone-resistant prostate can-
cer are marginally effective; thus, new agents are needed
to selectively kill cancer cells.
Curcumin, a polyphenolic compound that is extracted
from the rhizome of the plant Curcuma longa, has be-
come a focus of interest regarding its antitumor effects
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in multiple cancer cell types including prostate cancer
cells [2]. Moreover, curcumin is under clinical trials
mainly for cancer related diseases [3, 4]. Interestingly,
phase1 clinical trials already demonstrated the safety of
curcumin even at high doses (12 g/day). However, the
clinical advancement of this promising natural com-
pound is hampered by its poor water solubility and short
biological half-life, resulting in low bioavailability in both
plasma and tissues [5]. Multiple approaches are being
sought to overcome these limitations. In the past several
years, our lab has focused on the chemical modification
of curcumin to find novel molecules for drug develop-
ment [6, 7]. Previously, a series of mono-carbonyl ana-
logs of curcumin were synthesized and evaluated against
prostate cancer cells. Among them, compound WZ35
(Fig. 1a) exhibited good anti-prostate cancer activity at
the cellular level, with an IC50 of 2.2 μM, compared to
that of curcumin at 20.9μM in PC-3 cells (Fig. 1b), an
androgen-resistant and high metastatic potential human
prostate cancer cell lines.
Oxidative stress plays an important role in controlling
cancer cell behavior. Cancer cells may potentially benefit
from oxidative stress induction and the production of re-
active oxygen species (ROS), which are known to increase
the rate of mutations [8, 9]. However, the oxidative stress
response is a balance between pro-survival and pro-
apoptotic signaling pathways [10]. An uncontrolled high-
level ROS also triggers a series of pro-apoptotic signaling
pathways, including endoplasmic reticulum (ER) stress
and mitochondrial dysfunction, and ultimately leads to
cellular apoptosis [10]. Because cancer cells have a
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Fig. 1 Effects of curcumin analog WZ35 on cell viability and apoptosis in human prostate cancer cells. a The chemical structure of curcumin and
curcumin analog WZ35. b–c The effects of WZ35 or curcumin on cell viability in human prostate cancer cells. PC-3 cells or DU145 cells were
treated with WZ35 or curcumin at different concentration ranges as indicated for 48 h, then cell viability was determined by MTT assay, the IC50
was indicated. d Representative images for cell apoptosis stained with Annexin V-FITC/PI. Cells were treated with WZ35 at different concentrations
as indicated or curcumin (20 μM) for 24 h, then cells were stained with Annexin V-FITC/PI and analyzed by flow cytometry as described in
methods. e Western blot analysis for expression of apoptosis-associated proteins in cells treated with or without WZ35 or curcumin. Cells were
treated with WZ35 at different concentrations as indicated or curcumin (20 μM) for 24 h, the cell lysates were processed for western blot analysis
for protein expression of Bcl-2, Bax, pre-caspase 3, cleaved-PARP, and GAPDH used as a loading control. The statistic data were presented as
mean ± S.E from three independent experiments. *, p < 0.05, **, p <0.01; all versus DMSO group
Zhang et al. BMC Cancer  (2015) 15:866 Page 2 of 11
they are vulnerable to the acute induction of oxidative
stress that is caused by agents inducing ROS [9, 11].
Mounting evidence suggests that increasing oxidative
stress might be an effective strategy to eliminate cancer
cells. Increased ROS generation and oxidative stress
have been reported in prostate cancer cells [11]. Thus,
agents that can induce ROS generation may be effective
in killing prostate cancer cells.
The aim of this study was to determine the effect and
mechanism of WZ35 against prostate cancer cells. Our
data demonstrate that WZ35 showed strong antitumor
potential against PC-3 cells by activating ROS production
and subsequently inducing ER stress-dependent apoptosis
and cell cycle arrest.
Methods
Reagents
WZ35 (>98 % purity) was prepared in our lab using a
previously described method. Curcumin, N-acetylcysteine
(NAC), glutamine (L-GSH), dimethylsulfoxide (DMSO)
and methyl thiazolyl tetrazolium (MTT) were obtained
from Sigma-Aldrich (St. Louis, MO). The primary anti-
bodies, including anti-Bcl2 (sc-492), anti-Bax(sc-493),
anti-caspase 3 (sc-32577), anti-Cdc2 (sc-54), anti-Cyclin
B1 (sc-245), anti-MDM2 (sc-965), anti-GAPDH (sc-32233),
anti-p-PERK (sc-32577), horseradish peroxidase (HRP)-
conjugated (sc-2313) and phycoerythrin (PE)-conjugated
(sc-3755) secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The primary
antibodies, including anti-cleaved PARP (5625S), anti-p-
eIF2α (3398S), anti-ATF4 (11815S), and anti-CHOP
(2895S), were purchased from Cell Signaling Technology
(Danvers, MA). CHOP siRNA was purchased from Gene-
Pharma (Shanghai, China). FITC Annexin V apoptosis
Detection Kit I and propidium iodide (PI) were obtained
from BD Pharmingen (Franklin Lakes, NJ). Bradford pro-
tein assay kit, polyvinyldene fluoride membrane, ECL kit
were obtained from Bio-Rad (Hercules, CA). Lipofecta-
mine 2000, TRIZOL reagent, M-MLV Reverse Transcript-
ase Kit, PCR Supermix kit and primers for genes,
including CHOP and β-actin, were purchased from Invi-
trogen Life Technology (Carlsbad, CA). DCFH-DA was
obtained from Beyotime Biotech (Nantong, China).
Cell culture
Human prostate cancer PC-3 cells and DU145 cells were
obtained from the Shanghai Institute of Life Sciences
Cell Resource Center (Shanghai, China) and cultured in
DMEM/F12 medium (Gibco, Eggenstein, Germany) that
was supplemented with 10 % heat-inactivated FBS
(Hyclone, Logan, UT), 100 U/mL penicillin and 100 μg/mL
streptomycin (Mediatech Inc., Manassas, VA) in a humidi-
fied atmosphere of 5 % CO2 at 37 °C.
Methyl Thiazolyl Tetrazolium (MTT) assay
All of the experiments were carried out 24 h after the
cells were seeded. The tested compounds were dissolved
in DMSO and diluted with DMEM/F12 medium at dif-
ferent concentrations. The tumor cells were incubated
with test compounds for 48 h before the MTT assay. A
fresh solution of MTT (5 mg/mL) that was prepared in
PBS was added to each single well of the 96-well plate.
The plate was then incubated in a CO2 incubator for
4 h. Formazan cyrstals that formed in living cells was
dissolved in 150 μL of dimethyl sulfoxide, and the ab-
sorbance of the solution was measured at 490 nm using
a microplate reader (Reader 400 SFC, LabInstruments,
Hamburg,Germany). The IC50 values were calculated
using the GraphPad Prism 5 software.
Measurement of cell apoptosis
Apoptosis was analyzed by Annexin V-FITC/PI staining.
Briefly, after treatment, the cells were harvested and
washed with PBS followed by the addition of 1× binding
buffer (500 μl) and Annexin V-FITC (2 μl), incubated at
RT in the dark for 20 min and centrifuged. The cell pel-
let was re-suspended in 1× binding buffer, added with
3 μl of PI (30 μg/ml) and acquired immediately on an
FACS Caliber flow cytometer (BD Biosciences, CA). An
analysis was performed for Annexin V-FITC binding
using the FITC signal detector (FL-1) and PI staining by
the phycoerythrin emission signal detector (FL-2) using
the CellQuest™ software (BD Biosciences, CA) or the
FlowJo 7.6 software (TreeStar, San Carlos, CA).
Western blot assay
After treatment, the cells were collected and extracted
for total proteins. The protein concentrations in all of
the samples were determined using the Bradford protein
assay kit. Protein samples (30–100 μg) were subjected to
(10–15 %) sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and transferred onto polyvinyldene fluor-
ide membrane. After being blocked in blocking buffer
(5 % milk in tris-buffered saline containing 0.05 % Tween
20) for 1.5 h at room temperature, membranes were incu-
bated with different primary antibodies overnight at 4 °C.
Then, the membranes were washed in TBST and reacted
with secondary horseradish peroxidase-conjugated anti-
body for 1 h at room temperature, and the immunoreac-
tive bands were visualized using an ECL kit. The density
of the immunoreactive bands was analyzed using Image J
computer software (National Institute of Health, MD).
Determination of Reactive Oxygen Species (ROS)
production
Intracellular ROS generation was monitored by an FACS
Caliber flow cytometer (BD Biosciences, CA) using the
peroxide-sensitive fluorescent probe 2′,7′-dichlorofluorescin
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diacetate (DCFH-DA) as previously described [12]. In
brief, after treatment, the cells were incubated with 10 μM
DCFH-DA at 37 °C for 30 min, resuspended in ice-cold
phosphate buffered saline (PBS) and placed on ice in a
dark environment. The intracellular peroxide levels were
measured by an FACS Caliber flow cytometer that emitted
a fluorescence signal at 525 nm. Each group was acquired
for 10,000 individual cells using the CellQuest™ software
(BD Biosciences, CA) and analyzed by the FlowJo 7.6 soft-
ware (TreeStar, San Carlos, CA).
RT-qPCR assay
The total mRNA was isolated from cells using TRIZOL
Reagent according to the manufacturer’s instructions.
Reverse transcription and quantitative PCR were per-
formed using the M-MLV Reverse Transcriptase Kit and
PCR Supermix kit according to the manufacturer’s in-
structions. Real-time qPCR was carried out using the
Eppendorf Real plex 4 instrument (Eppendorf, Hamburg,
Germany). The relative amount of each gene was nor-
malized to the amount of β-actin. The primer sequences
used were shown as followed. Human CHOP: forward,
CAGAACCAGCAG AGGTCACA; reverse, GCTGTG
CCACTTTCCTTTC. Human β-action: forward, TCCT
TCCTGGGCATGGAGTC; reverse, GTAACGCAACT
AAGTCATAGTC.
Transient transfection of small interfering RNA (siRNA)
The cells were transfected with siRNA (50pmol/ml) tar-
geting CHOP or non-targeted siRNA as a control using
the lipofectamine 2000 reagent as described by the man-
ufacturer’s instructions. Subsequently, the transfected
cells were washed and changed with complete media
and used in further studies. The siRNA sequences used





siRNA sequences were adopted according to previous
published work [13].
Cell cycle analysis
The cell cycle status and nuclear DNA contents were de-
termined using propidium iodide (PI) staining and flow
cytometry. Briefly, the cells were collected, fixed with
75 % ice-cold ethanol and stored at 4 °C for 24 h. After
they were washed with PBS, the cells were stained with
PI [50 μg/ml PI and 10 μg/ml ribonuclease (RNase) in
PBS] at 4 °C for 20 min in the dark. The cells were
washed and subjected to an FACS Caliber flow cytomet-
ric analysis of the DNA content. The cell fractions in the
G2/M phase were used for statistical analysis using the
FlowJo 7.6 software (TreeStar, San Carlos, CA).
Immunofluorescence assay for CHOP
Cells were fixed with 4 % paraformaldehyde and perme-
abilized with 100 % methanol at -20 °C for 5 min. After
fixation and permeabilization, the cells were washed
twice with PBS containing 1 % BSA and then incubated
with the primary antibody for CHOP overnight at 4 °C,
followed by incubation with the PE-conjugated second-
ary antibody. Then, the cells were counterstained with
DAPI and viewed under a Nikon fluorescence micro-
scope (400× amplification; Nikon, Japan).
Statistical analysis
All of the experiments were performed independently
three times. The data are presented as means ± SE. The
statistical significance of differences between groups was
obtained by the student’s t-test or ANOVA multiple
comparisons in GraphPad Pro (GraphPad, San Diego,
CA). Differences were considered significant at *, P < 0.05;
**, P <0.01; ***, P <0.001.
Results
WZ35 reduced cell viability and induced cell apoptosis in
human prostate cancer cells
To determine the cytotoxic effects of WZ35 in prostate
cancer cell lines, an MTT assay was performed to evalu-
ate the viability in human prostate cancer PC-3 and
DU145 cells. As shown in Fig. 1b and c, WZ35 or curcu-
min treatment significantly decreased the viability of
PC-3 cells and DU145 cells in a dose-dependent manner.
The IC50 value for WZ35 and curcumin was 2.2 μM ver-
sus 20.9 μM in PC-3 cells, and 2.8 versus 31.7 μM in
DU145 cells, respectively, indicating a much better anti-
cancer ability of WZ35 than curcumin. We then evaluated
the role of apoptosis in WZ35-induced cell death using
Annexin V-FITC/PI staining. A time-course assay revealed
that the occurrence of cell apoptosis induced by WZ35
began at 12 h and peaked at 24 h after WZ35 treatment
(Additional file 1: Figure S1A). The exposure of PC-3 cells
to WZ35 at various concentrations for 24 h dose-
dependently increased the number of apoptotic cells
(Fig. 1d). In addition, WZ35 was dramatically more effect-
ive than curcumin in apoptosis induction. The levels of
apoptosis-associated proteins were also examined by west-
ern blot analysis in PC-3 cells. As shown in Fig. 1e, WZ35
treatment decreased the protein level of Bcl-2 and pro-
caspase 3 and increased the cleaved PARP in a dose-
dependent manner but had no effect on Bax expression.
No obvious changes were observed in these protein levels
in cells that were treated with 20 μM curcumin (Fig. 1e).
ROS overproduction mediated WZ35-induced apoptosis
in PC-3 cells
We investigated whether intracellular ROS generation
was implicated in the anti-cancer effects of WZ35. The
Zhang et al. BMC Cancer  (2015) 15:866 Page 4 of 11
ROS level was assessed by using fluorescent probe
DCFH-DA that detected H2O2. Interestingly, WZ35
treatment significantly increased intracellular ROS gen-
eration in a time-dependent manner (Fig. 2a). Further-
more, co-treatment with N-acetylcysteine (NAC), an
ROS scavenger, significantly inhibited WZ35-induced
ROS generation (Fig. 2b). These data show that WZ35
could induce the accumulation of ROS in prostate can-
cer cells. We then examined whether increased ROS was
required for cell apoptosis induced by WZ35. As shown
in Fig. 2c, co-treatment with NAC at the concentration
of 10 mM almost completely abrogated WZ35-induced
cell apoptosis. In addition, reversed cell apoptosis was
also observed in WZ35-treated cells in the presence of
glutathione (L-GSH), another potent antioxidant that
has been widely used to define the function of ROS in
numerous biological and pathological processes (Fig. 2d).
Collectively, these results indicated that ROS generation
plays a central role in mediating WZ35-induced cell
apoptosis.
WZ35-induced cell apoptosis through ER stress-mediated
CHOP expression in PC-3 cells
ROS generation has been reported to activate multiple
pro-apoptotic cascades, including the ER stress-induced
cancer cell apoptosis pathway [10, 14]. Thus, we
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Fig. 2 WZ35 induced cell apoptosis is via oxidative stress. a The time-course ROS generation induced by WZ35. Cells were treated with WZ35
(10 μM) for different time as indicated, then cells were strained with DCFH-DA and the DCF fluorescence intensity was analyzed with flow cytometry.
b Representative image for ROS generation in cells treated with WZ35 in the presence or absence of NAC. Cells were treated with WZ35 (10 μM) in
the presence or absence of NAC (10 mM) for 9 h, then cells were stained with DCFH-DA and DCF fluorescence intensity was analyzed by flow
cytometry as described in methods. The relative increase in DCF fluorescence intensity was indicated. c–d Representative images for cell apoptosis
stained with Annexin V-FITC/PI. Cells were treated with WZ35 (10 μM) in the presence or absence of NAC (10 mM) or L-GSH (10 mM) for 24 h, then
cells were stained with Annexin V-FITC/PI, and analyzed by flow cytometry as described in methods. The statistic data were presented as mean ± S.E
from three independent experiments. **, p <0.01; ***, p <0.001
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determined the effects of treatment with WZ35 on the
induction of ER stress. When PC-3 cells were treated
with WZ35 for various time intervals, we noticed a tran-
sient increase in the level of phosphorylated PERK, com-
mencing after 2 h of treatment with WZ35 and
remaining elevated for up to 4 h (Fig. 3a). WZ35 treat-
ment also induced a constant increase in the level of
phosphorylated eIF2α 3 to 12 h after WZ35 treatment
(Fig. 3a). ATF4 expression also increased in a similar
manner with p-eIF2α (Fig. 3a).
CHOP is considered a marker of the commitment of
ER stress-induced apoptosis. Western blotting analysis
further showed that CHOP protein expression appar-
ently increased 9-24 h after WZ35 treatment and peaked
at 12 h (Fig. 3a). Similar time-course results were also
observed in the mRNA level of CHOP induction
(Fig. 3b). Figure 3c shows that compound WZ35 in-
duced CHOP mRNA up-regulation in a dose-dependent
manner. These results suggest that WZ35 can induce ER
stress in prostate cancer cells. In order to further con-
firm that ER stress plays an important role in the induc-
tion of PC-3 cell apoptosis by WZ35, we constructed the
siRNA for CHOP gene silencing. PC-3 cells were trans-
fected with the CHOP siRNA sequence or the control
ATF4
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Fig. 3 WZ35 induced cell apoptosis through ER stress-mediated CHOP expression in PC-3 cells. a–b The time-course expression of ER stress
markers induced by WZ35. Cells were treated with WZ35 (10 μM) at different time interval as indicated, then cells were processed for western blot
analysis or RT-qPCR for expression of ER stress markers such as p-PERK, p-eIF2α, ATF4, and CHOP as described in methods, and GAPDH or β-actin
was used as a loading control. c The mRNA expression of CHOP in cells treated with WZ35. Cells were treated with WZ35 at different concentrations
as indicated for 12 h, then the mRNA expression of CHOP was detected with RT-qPCR assay as described in methods, and β-actin was used as a
loading control. d–g The effects of CHOP-siRNA on cell apoptosis induced by WZ35. Cells were transfected with Ctrl siRNA or CHOP siRNA for 24 h as
described in methods. Then the transfected cells were treated with or without WZ35 (10 μM) for 24 h. Then the cells were processed for western blot
analysis for CHOP expression (d) or processed for CHOP immunofluoresence staining (e) or stained with Annexin V-FITC/PI followed by flow cytometry
analysis (f) or processed to western blot analysis for cleaved-caspase3 expression (g), as described in methods. The statistic data were presented as
mean ± S.E from three independent experiments. *, p <0.05, versus Ctrl siRNA +WZ35 group
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sequence. Western blot analysis demonstrated that the
transfection of CHOP siRNA resulted in a significant de-
crease in CHOP expression in WZ35-treated PC-3 cells
(Fig. 3d), compared to cells that were transfected with
control scrambled siRNA. This result was further con-
firmed by immunofluorescence staining (Fig. 3e). Further-
more, to confirm that a reduction of CHOP expression
inhibits WZ35-induced PC-3 cell apoptosis, we treated
CHOP siRNA-transfected PC-3 cells with WZ35. Figure 3f
shows that when CHOP expression in PC-3 cells was si-
lenced, cell apoptosis induced by WZ35 was significantly
reduced compared to that of the control group (P < 0.05).
Furthermore, the protein level of cleaved-caspase 3 in-
duced by WZ35 was also reduced in CHOP-knockdown
PC3 cells (Fig. 3g). Taken together, these results indicate
that WZ35-induced cell apoptosis is, at least partly, medi-
ated by the ER stress pathway.
WZ35 induced cell cycle arrest in G2/M phase in PC-3
cells
To determine the anti-mitogenic effect of WZ35, we
performed a cell-cycle analysis in PC-3 cells. As shown
in Fig. 4a, WZ35 treatment induced the accumulation of
cells in the G2/M phase in a dose-dependent manner.
The effect of 10 μM WZ35 on cell cycle arrest was
stronger than that of curcumin at 20 μM (Fig. 4a). In
addition, the cell population in S phase were reduced, in
association with the increased cell population in the G2/
M phase, and no changes were observed in the G0 phase
(Additional file 1: Figure S1B). We further tested the ef-
fects of WZ35 on cell cycle arrest-related proteins by
western blot analysis. G2/M transition is regulated by
the cyclin B1/CDC2 complex [15], and MDM2 is a nega-
tive regulator of p21, which is involved in the G2/M
checkpoint and is required for cell cycle arrest in the
G2/M2 phase [16, 17]. Figure 4b–d reveals that WZ35
treatment decreased the protein level of CDC2, Cyclin
B1, and MDM2 in a dose-dependent manner, while cur-
cumin treatment at 20 μM has no significant effects on
these proteins. These results suggest an anti-mitogenic
effect of WZ35 in PC-3 cells.
Both ER stress and G2/M arrest induced by WZ35 were
mediated by ROS generation in PC-3 cells
Because ROS production induced by WZ35 occurs
within a relatively much earlier time (30 min), compared
to ER stress activation and cell cycle arrest, we supposed
that ROS generation might be the upstream incidence in
the procedure of WZ35-induced PC-3 cell death. Thus,
we determined whether ROS generation is required for
WZ35-induced ER stress and G2/M arrest in PC-3 cells.
As shown in Fig. 5a, co-treatment with the ROS
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Fig. 4 WZ35 induced cell cycle arrest in the G2/M phase in PC-3 cells. Cells were treated with WZ35 at different concentrations as indicated or
curcumin (20 μM) for 24 h, then cells were processed for cell cycle analysis (a) or western blot analysis for expression of cell cycle-associated
proteins (b–d) as described in methods. The statistic data were presented as mean ± S.E from three independent experiments. *, p < 0.05, **,
p <0.01; ***, p <0.001; all versus DMSO group
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scavenger NAC markedly inhibited the WZ35-induced
over-expression of ER stress markers. A similar result
was also observed at the mRNA level of CHOP induced
by WZ35 in the presence of NAC (Fig. 5b). These results
indicate that WZ35-induced ER stress is mediated by in-
creased oxidative stress. As expected, co-treatment with
NAC also significantly inhibited the WZ35-induced ac-
cumulation of cells in the G2/M phase (Fig. 5c). In
agreement, western blot analysis revealed that co-
treatment with NAC significantly reversed the decreased
protein level of CDC2 and CyclinB1 induced by WZ35
in PC-3 cells (Fig. 5d and e).
Discussion
In the present study, we demonstrated that a new novel
curcumin analog WZ35 showed excellent anticancer
effects in prostate cancer cells via inducing ROS-
dependent ER stress and G2/M cell cycle arrest. These
findings indicate that WZ35 should be further explored
as an effective anticancer agent for the treatment of
prostate cancer. Accumulating evidence suggests that in-
creasing oxidative stress might be an effective strategy to
eliminate cancer cells [18]. Agents with the potential to
induce ROS generation have anticancer effects in prostate









































































Fig. 5 Both ER stress and G2/M arrest induced by WZ35 were mediated by ROS generation. a–b The ROS scavenger NAC reversed WZ35-induced
ER stress. Cells were treated with WZ35 (10 μM) in the presence or absence of NAC (10 mM) for 24 h, then cells were processed for western blot
analysis or RT-qPCR assay for the expression of ER stress markers as described in methods. c–e The ROS scavenger NAC reversed WZ35-induced
G2/M arrest. Cells were treated with WZ35 (10 μM) in the presence or absence of NAC (10 mM) for 24 h, then cells were processed for cell cycle
analysis (c) or western blot analysis for expression cell cycle-associated proteins (d–e) as described in methods. f The mechanism scheme of the
anti-prostate cancer effects of WZ35. The statistic data were presented as mean ± S.E from three independent experiments. *, p < 0.05, **, p <0.01;
all versus WZ35 group
Zhang et al. BMC Cancer  (2015) 15:866 Page 8 of 11
[20] and WZC02-9 [21]. Herein, increased ROS gener-
ation was also observed in WZ35-treated PC-3 cells
(Fig. 2). Importantly, the abrogation of ROS production by
NAC co-treatment almost completely reversed the WZ35-
induced cell apoptosis, suggesting the significant involve-
ment of ROS in WZ35-induced cell death. Thus, our re-
sults further indicate that developing agents with inducing
ROS potential will be a good strategy for cancer therapy.
Recently, ER stress-induced cancer cell apoptosis has
become a novel signaling target for the development of
cancer therapeutic drugs [22–24]. Various pathological
conditions, such as hypoxia, ER-Ca2+ depletion, oxida-
tive injury, hypoglycemia and viral infections, may cause
an imbalance between the protein folding load and cap-
acity; this cellular condition is known as ER stress [25].
The initial role of ER stress is tailored to re-establish ER
homeostasis. However, when ER stress is too severe or
cannot be solved, it changes from a pro-survival to a
pro-death response, culminating in the activation of in-
trinsic apoptosis [26]. The most important pathway
translating the cell from ER stress to death is the PERK/
eIF2α pathway [14]. The phosphorylation of PERK/eIF2α
subsequently induces the expression of transcription fac-
tors ATF4 and CHOP, which are important elements
triggering the pro-apoptotic signaling [27]. Here, we
found that WZ35 induced PERK/eIF2α activation and
ATF4/CHOP expression in a time-course manner, indi-
cating that WZ35 activated pro-apoptotic ER stress sig-
naling (Fig. 3a–c). Then, we found that WZ35-mediated
apoptosis was partially reduced in CHOP-deficient cells,
confirming the mediation of ER stress in WZ35-induced
cell apoptosis (Figure F). Similar to that of WZ35, tar-
geting ER stress to induce cancer cell death has been
reported by our previous works for other monocarbo-
nyl analogs of curcumin such as B19 [28], B63 [29] and
B82 [30].
Increased oxidative stress is linked to ER stress activa-
tion [25]. ROS could exacerbate protein misfolding in
the ER lumen by oxidizing amino acids in folding pro-
teins or by modifying chaperone and/or ERAD function,
thereby amplifying unfolding protein response (UPR)
signaling [31]. Increased ROS generation or oxidative
stress may be responsible for subsequent ER stress and
ER stress-dependent cell apoptosis. Antioxidants reduce
ER stress and improve cell survival [32]. However, an in-
verse relationship between oxidative stress and ER stress
has also been reported by Jypti D et al. [32]. The authors
found that the accumulation of unfolded protein in the
ER lumen is sufficient to produce ROS and suggested
that unfolded protein in the ER lumen signalsROS pro-
duction as a second messenger to activate the UPR and
induce apoptosis [32]. In this study, we found that ER
stress activated by WZ35 was almost completely re-
versed by the presence of NAC, a ROS scavenger (Fig. 5).
In addition, WZ35 treatment activated ROS generation
within 30 min, much earlier than the treatment time for
ER stress induction. Thus, these results indicate that the
increased ROS generation induced by WZ35 is required
for the induction of ER stress and triggers ER stress-
dependent apoptosis in PC-3 cells.
The present study also shows that WZ35 treatment
inhibited G2/M progression in prostate cancer cells, in
association with the decreased expression of CDC2,
cyclinB1, and MDM2 (Fig. 4). As each phase of the cell
cycle is driven by specific CDKs, the CDK1 (also named
CDC2)-cyclin B1 complex is responsible for driving cells
through mitosis [15]. MDM2 is an oncoprotein that can
regulate the cell cycle and is a negative regulator of p21,
which is required for cell cycle arrest in the G2/M2
phase [16, 17]. Several studies have reported that some
compounds inducing ROS generation, including diallyl
trisulfide [23], plumbagin [33], and diallyl disulfide [25],
could induce cell cycle arrest at the G2/M phase in sev-
eral cancer cells. Here, we also found the WZ35-induced
G2/M arrest was reversed by co-treatment with an ROS
scavenger (Fig. 5). These results suggest a strong link be-
tween oxidative stress and cell cycle arrest. Although
this link has been also observed in other anti-cancer
therapies, the underling mechanism has not been totally
resolved. Some studies reported that p21 plays a vital
role in mediating ROS-induced G2/M arrest [34]. In
addition, a p21-independent mechanism has also been
reported [20]. Xiao et al. revealed that increased ROS
can induce the destruction and hyperphosphorylation of
CDC25c, a phosphatases that can dephosphorylate CDK1
in Thr14 and Tyr15, and hence activate the CDK1/
cyclinB1 kinase complex [20]. Although our study demon-
strates that the ROS-induced cell cycle arrest is associated
with CDC2/cyclin B1 reduction, the exact mechanism re-
quires further research.
The excellent anticancer effects of WZ35 suggest the
potential advantages of the mono-carbonyl structure of
curcumin. Our group has been engaged in designing and
discovering new small molecules from natural curcumin.
Previously, some other monocarbonyl analogs of cur-
cumin, such as B19 [28], B63 [29], and B82 [30], that
were synthesized by our lab were demonstrated to pos-
sess strong anti-cancer effects in various cancer cells.
In addition, we investigated the mechanism by which
these compounds induce cancer cell death. As previ-
ously reported, one common mechanism underling
their anticancer action is that all of these agents could
induce lethal ER stress. This result is also observed in
the anti-cancer effects of WZ35. However, our previ-
ous studies have failed to demonstrate how curcumin
analogs activate ER stress. In the present study, we
found that WZ35-increased ROS generation occurred
upstream of ER stress. This mechanism may be also
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suitable for previously reported mono-carbonyl ana-
logs of curcumin.
In addition, similar results were observed in DU145
cells. As shown in Additional file 1: Figure S2, we found
that WZ35 also induced ROS accumulation, CHOP ex-
pression, cell apoptosis and G2/M arrest in DU145 cells.
More importantly, all of these alterations were signifi-
cantly inhibited by ROS scavenger NAC pretreatment,
and the genetic silence of CHOP by siRNA approach
also remarkably prevented cell apoptosis in DU145 cells.
Collecting the data from DU145 and PC-3 cells, our re-
sults vividly demonstrate the pivotal role of the ROS-ER
stress signaling pathway in mediating the anticancer ef-
fects of WZ35 in prostate cancer cells.
Conclusions
In summary, a new monocarbonyl analog of curcumin,
WZ35, exhibited antitumor effects on human PC-3 and
DU145 cells in vitro by inducing ROS generation and
subsequent ER stress and G2/M cycle arrest. The discov-
ery of the activation of ROS-mediated apoptosis by the
curcumin analog WZ35 may provide new strategy for
curcumin-based anticancer drug design and develop-
ment. The new compound WZ35 could be further ex-
plored as a potential anticancer agent for the treatment
of prostate cancer.
Additional file
Additional file 1: The anti-cancer effects of WZ35 treatment in PC-
3 and DU145 cells. Figures S1, The time-course of cell apoptosis and
cell cycle progression in response to WZ35 treatment in PC-3 cells. and
S2, The effects of WZ35 treatment in DU145 cells.(DOC 290 kb)
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